Pevifoscorvir-sodium, Publications Immune-modulatory effects of pevifoscorvir sodium in HBeAg-positive patients with chronic hepatitis B infection
Pevifoscorvir-sodium, Publications Pevifoscorvir Sodium Reduces HBsAg Levels to < 3000 IU/mL in HBeAg Positive Subjects with Chronic HBV Infection Following Long-Term On-Study Treatment
Pevifoscorvir-sodium, Publications Pevifoscorvir Sodium (CAM-E) is Superior to Nucleos(t)ide Analogs in Suppressing Hepatitis B Virus Double-stranded Linear DNA In Vitro
Pevifoscorvir-sodium, Publications ALG-001075, the parent of pevifoscorvir sodium, exhibits potent in vitro antiviral properties compared to other HBV capsid assembly modulators in clinical development
Pevifoscorvir-sodium, Publications Potent and durable off-treatment reduction of HBsAg levels and cccDNA-derived transcripts by the CAM-E ALG-001075 in cell-based experiments
Pevifoscorvir-sodium, Publications Sustained reduction of HBV antigen levels at ≥6 months follow-up in HBeAg-positive participants with chronic hepatitis B infection after 96 weeks of 300 mg pevifoscorvir sodium monotherapy
Pevifoscorvir-sodium, Publications Pevifoscorvir sodium demonstrated profound antiviral activity in untreated HBeAg+ subjects, regardless of baseline ALT level
Pevifoscorvir-sodium, Publications Population pharmacokinetics of pevifoscorvir sodium (ALG-000184) in healthy participants and participants with chronic hepatitis B in support of phase 2 dose selection
Pevifoscorvir-sodium, Publications Capsid Assembly Modulator ALG-001075 Prevents CCCDNA Formation and HBV DNA Integration in Vitro
Pevifoscorvir-sodium, Publications High Viral Suppression in Chronic HBV Infection Subjects with Pevifoscorvir Sodium Monotherapy